The good news, I guess, is that we have very many different treatment options for relapse refractory multiple myeloma, and some of that is considered in the background of what we do for patients with ...

Disparities in multiple myeloma outcomes and the need for equitable care were the focus of 2 posters presented at the 2025 ...

Why do some patients with precursors to bone marrow cancer never develop the disease? Researchers from the Department of ...

Formal communication could help ease the transition of care from specialized myeloma centers to community clinic, according ...

During a live event, Taewoong Choi, MD, discussed the potential use of quadruplet in transplant-ineligible multiple myeloma ...

SE (NASDAQ:ARGX) said on Friday that it has received approval from the European Commission for its IgG Fc-antibody fragment, ...

A older male patient was diagnosed with multiple myeloma (MM) and retroperitoneal fibrosis secondary to immunoglobulin G4-related disease (IgG4-RD), as discussed in a case report published in the ...

Hypogammaglobulinemia either as an adverse reaction or laboratory IgG level below 500mg/dl, after infusion occurred in 94% (267/285) of patients treated. ... ABOUT MULTIPLE MYELOMA.

Significant advances in treatment paradigms for multiple myeloma (MM) have been seen recently, with over 14 treatments approved by the US Food and Drug Administration (FDA) in the past decade alone. 1 ...

According to safety and efficacy data from the MajesTEC-2 (NCT04722146) and TRIMM‑2 (NCT04108195) trials, the combination of teclistamab-cqyv (Tecvayli), daratumumab (Darzalex), and pomalidomide ...

Multiple myeloma is the second most common form of blood cancer. ... Among these, IgG myeloma is the most common, followed by IgA myeloma. 2. Light chain multiple myeloma.